Merck's dual orexin receptor antagonist suvorexant is approaching the regulatory finish line, 15 years after orexins were discovered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Osborne, R. First-in-class insomnia drug on the brink of approval nod. Nat Rev Drug Discov 12, 492–493 (2013). https://doi.org/10.1038/nrd4067
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4067